Attention Investors : Prevent Unauthorized Transactions in your Trading / demat account -->Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. Update your Mobile Number & e mail id with your Broker / Depository Participant. Receive alerts on your Registered Mobile for all Transactions / debit and other important transactions in your Trading / demat account directly from Exchanges & CDSL on the same day. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month......... Issued in the interest of investors. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. SCORES - Filing compliant on SCORES – Easy & quick    a. Register on SCORES portal.    b. Mandatory details for filing complaints on SCORES : Name, PAN, Address, Mobile Number, Email ID.    c. Benefits : Effective communication . Speedy redressal of the grievances Website : https://scores.sebi.gov.in/ Head Office / ARN Desk Backoffice Employee Sub-Broker/Sale Manager Branch Client Quotes NAV Insurance NAV

ipo  IPO Forthcoming IPO's Open / Current IPO's Closed IPO's New Issue Monitor New Listing Basis of Allotment Draft Prospectus Best Performers IPO News Know IPO's / FAQ's Equities | Mutual Funds | Commodities | Derivatives | IPO | Insurance Products & Services    >   IPO   >   Synopsis Details Q-Line Biotech Ltd Registered Office:    298-281 Transport Nagar Kanpur ,   #NAME? ,   Lucknow - 226012 ,   Uttar Pradesh , India.   Phone: +91 522 2435 570   Fax: compliance@qlinebiotech.com   Website:www.qlinebiotech.com Initial public offer of upto 62,53,200 equity shares of face value of Rs. 10/- each (the "Equity Shares") of Q-Line Biotech Limited ("the Company" or "QLBL" or "the Issuer") at an issue price of Rs. 326-343 per equity share (including share premium of Rs. 316-333 per equity share) for cash, aggregating up to Rs. 203.85-214.48 Crores ("Public Issue") out of which 3,13,200 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 326-343 per equity share for cash, aggregating Rs. 10.21-10.74 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 59,40,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 326-343 per equity share for cash, aggregating upto Rs. 193.64-203.74 Crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute 26.81% and 25.46% respectively of the post- issue paid-up equity share capital of the company. The company, in consultation with the book running lead managers, may consider a pre-ipo placement of up to 8,00,000 equity shares for cash consideration ("pre-ipo placement") prior to filing of the pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the book running lead managers. If the pre-ipo placement is undertaken, the number of equity shares issued pursuant to the pre-ipo placement shall be reduced from the issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) rules, 1957, as amended ("scrr"). Price Band: Rs. 326 to Rs. 343 per equity share of face value Rs. 10/- each. The floor price (Rs.326) is 32.6 times the face value of the equity shares and the cap price (Rs.343) is 34.3 times of the face value of the equity shares. Bids can be made for a minimum of 800 equity shares and in multiples of 400 equity shares thereafter. Issue Money Payable On Opens On Closes On Application Allotment 21-May-26 25-May-26 Rs 326.00-343.00 Rs 0.00-0.00 Minimum Application for shares in Nos : 800   Further Multiples of : 400 Q-Line Biotech Ltd   Rs Cr Lead Managers to the Issue Project Cost 0.00 Hem Securities Limited Share India Capital Services Private Limited Project Financed through Current Offer 203.85   Post Issue Equity Share Capital 23.33   Issue Price Rs. 326.00   Projects To meet Working Capital requirements Repayment of certain borrowing availed by the Company, in part or full General corporate purposes Promoted By Saurabh Garg Amita Garg Ayush Garg Listing At NSE - SME Registrar to the Issue                SEBI Common Reg. No. INZ000206338          MAPIN NO:10014845        CDSL : IN-DP-CDSL-291-2005 MERCHANT BANKING REGISTRATION NO : NM000011575 Terms of the Site   I   Privacy Policy   I  Disclaimer   I  Broker Norms   I  Attention and Advisory for Investors   I  Investor Relations   I  Investor Charter   I  Site Map   I  Payment Gateway   I  Circular   I  Upfront Margin   I  Pricing   I  Investor Complaints   I  Depository Participant   I  Investor Complaints for DP   I  CDSL E-Voting   I  Maintenance of Website   I   Details of authorized persons   I   SMART ODR   I   Bank Details   I   View Client Collateral Details   I   Ekyc Login   I   Online KYC Closure INTERNAL CONTROL POLICY  I  AML POLICY  I  RMS POLICY  I  POLICIES & PROCEDURES  I  CLIENT ACCEPTANCE POLICY   I   CLIENT REGISTRATION FORM KYC Form Mandatory Document   I   DOCUMENTS IN VERNACULAR LANGUAGES BSE  I  NSE  I  CDSL  I  SEBI  I  MCX  I  NCDEX © 2010 SHARE MART. All rights reserved Designed, Developed and Maintained by CMOTS Infotech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)